A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia

Journal of Clinical Lipidology

Volumn 10, Issue 5, 2016, Pages 1153-1162.e3

  Langslet, Gisle ^a   Breazna, Andrei ^b   Drogari, Euridiki ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adolescents; Atorvastatin; Children; Heterozygous familial hypercholesterolemia; Low density lipoprotein cholesterol; Tanner stage

Indexed keywords

ATORVASTATIN; BILIRUBIN; CREATINE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN B100; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADOLESCENT; ARTICLE; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CONSTIPATION; COUGHING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; EWING SARCOMA; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; HYPERPLASIA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; BLOOD; CLINICAL TRIAL; GENETICS; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; PATHOLOGY; SARCOMA, EWING; SEXUAL DEVELOPMENT;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; ATORVASTATIN CALCIUM; CHILD; CHOLESTEROL, LDL; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPERPLASIA; MALE; RECEPTORS, LDL; SARCOMA, EWING; SEX CHARACTERISTICS;

EID: 84979500048     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.05.010     Document Type: Article

References (44)

1. 1 Berenson, G.S., Srinivasan, S.R., Bao, W., Newman, W.P. 3rd, Tracy, R.E., Wattigney, W.A., Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 338:23 (1998), 1650–1656.
2. 2 Juonala, M., Magnussen, C.G., Venn, A., et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation 122:24 (2010), 2514–2520.
3. 3 McCrindle, B.W., Urbina, E.M., Dennison, B.A., et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 115:14 (2007), 1948–1967.
4. 4 Hopkins, P.N., Toth, P.P., Ballantyne, C.M., Rader, D.J., Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5:3 Suppl (2011), S9–S17.
5. 5 Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34:45 (2013), 3478–3490a.
6. 6 Stein, E.A., Raal, F.J., Polygenic familial hypercholesterolaemia: does it matter?. Lancet 381:9874 (2013), 1255–1257.
7. 7 Arca, M., Zuliani, G., Wilund, K., et al. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 359:9309 (2002), 841–847.
8. 8 Wiegman, A., Gidding, S.S., Watts, G.F., et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 36 (2015), 2425–2437.
9. 9 Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 142:1 (1999), 105–112.
10. 10 Mundal, L., Sarancic, M., Ose, L., et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010. J Am Heart Assoc, 3(6), 2014, e001236.
11. 11 Goldstein, J.M., The Metabolic Basis of Inherited Diseases. 2001, McGraw-Hill Information Services, New York.
12. 12 Wiegman, A., de Groot, E., Hutten, B.A., et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 363:9406 (2004), 369–370.
13. 13 Kusters, D.M., Wiegman, A., Kastelein, J.J., Hutten, B.A., Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res 114:2 (2014), 307–310.
14. 14 Neil, A., Cooper, J., Betteridge, J., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 29:21 (2008), 2625–2633.
15. 15 Versmissen, J., Oosterveer, D.M., Yazdanpanah, M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ, 337, 2008, a2423.
16. 16 Braamskamp, M.J., Kastelein, J.J., Kusters, D.M., Hutten, B.A., Wiegman, A., Statin Initiation During Childhood in Patients With Familial Hypercholesterolemia: Consequences for Cardiovascular Risk. J Am Coll Cardiol 67:4 (2016), 455–456.
17. 17 Avis, H.J., Hutten, B.A., Gagne, C., et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 55:11 (2010), 1121–1126.
18. 18 Braamskamp, M.J., Langslet, G., McCrindle, B.W., et al. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. J Clin Lipidol 9:6 (2015), 741–750.
19. 19 Clauss, S.B., Holmes, K.W., Hopkins, P., et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 116:3 (2005), 682–688.
20. 20 de Jongh, S., Ose, L., Szamosi, T., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106:17 (2002), 2231–2237.
21. 21 Gandelman, K., Glue, P., Laskey, R., Jones, J., LaBadie, R., Ose, L., An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatr Cardiol 32:4 (2011), 433–441.
22. 22 Knipscheer, H.C., Boelen, C.C., Kastelein, J.J., et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 39:5 (1996), 867–871.
23. 23 Vuorio, A., Kuoppala, J., Kovanen, P.T., et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev, 7, 2014, CD006401.
24. 24 Wiegman, A., Hutten, B.A., de Groot, E., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292:3 (2004), 331–337.
25. 25 Stein, E.A., Illingworth, D.R., Kwiterovich, P.O. Jr., et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 281:2 (1999), 137–144.
26. 26 McCrindle, B.W., Ose, L., Marais, A.D., Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 143:1 (2003), 74–80.
27. 27 Kusters, D.M., Avis, H.J., de Groot, E., et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA 312:10 (2014), 1055–1057.
28. 28 Braamskamp, M.J., Stefanutti, C., Langslet, G., et al. Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk. J Pediatr 167:2 (2015), 338–343.e5.
29. 29 Lamaida, N., Capuano, E., Pinto, L., Capuano, R., Capuano, V., The safety of statins in children. Acta Paediatr 102:9 (2013), 857–862.
30. 30 Simova, I.I., Denchev, S.V., Dimitrov, S.I., Effects of statins on endothelial function in patients with coronary artery disease. Clin Cardiol 32:4 (2009), 193–198.
31. 31 de Jongh, S., Lilien, M.R., op't Roodt, J., Stroes, E.S., Bakker, H.D., Kastelein, J.J., Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 40:12 (2002), 2117–2121.
32. 32 Jones, P.H., McKenney, J.M., Karalis, D.G., Downey, J., Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J, 149(1), 2005, e1.
33. 33 de Ferranti, S., Ludwig, D.S., Storm over statins–the controversy surrounding pharmacologic treatment of children. N Engl J Med 359:13 (2008), 1309–1312.
34. 34 Marshall, W.A., Tanner, J.M., Variations in pattern of pubertal changes in girls. Arch Dis Child 44:235 (1969), 291–303.
35. 35 Marshall, W.A., Tanner, J.M., Variations in the pattern of pubertal changes in boys. Arch Dis Child 45:239 (1970), 13–23.
36. 36 World Health Organization. Height-for-age GIRLS: 5 to 19 years (z-scores). http://www.who.int/growthref/cht_hfa_girls_z_5_19years.pdf?ua=1. Published 2007. Accessed August 17, 2015.
37. 37 World Health Organization. Height-for-age BOYS: 5 to 19 years (z-scores). http://www.who.int/growthref/cht_hfa_boys_z_5_19years.pdf?ua=1. Published 2007. Accessed August 17, 2015.
38. 38 Ryan, A., Byrne, C.D., Importance of early recognition of heterozygous familial hypercholesterolaemia. Curr Opin Lipidol, 26(4), 2015, 6.
39. 39 Baigent, C., Blackwell, L., Emberson, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:9753 (2010), 1670–1681.
40. 40 Newman, C., Tsai, J., Szarek, M., Luo, D., Gibson, E., Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 97:1 (2006), 61–67.
41. 41 Goldberg, A.C., Hopkins, P.N., Toth, P.P., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5:3 Suppl (2011), S1–S8.
42. 42 Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128 Suppl 5 (2011), S213–S256.
43. 43 Rodenburg, J., Vissers, M.N., Wiegman, A., et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 116:6 (2007), 664–668.
44. 44 Braamskamp, M.J., Kusters, D.M., Avis, H.J., et al. Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence. Paediatr Drugs 17:2 (2015), 159–166.